Immunotherapy duo plus radiation shows promise in lung cancer trial
NCT ID NCT04013542
First seen Oct 31, 2025 · Last updated May 22, 2026 · Updated 23 times
Summary
This early-phase trial is testing whether combining two immunotherapy drugs (ipilimumab and nivolumab) with radiation therapy is safe and effective for people with stage II or III non-small cell lung cancer that cannot be removed by surgery. The goal is to see if this approach can help the immune system fight the cancer better than standard chemotherapy with radiation. The study enrolled 21 participants and is no longer recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG NON-SMALL CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.